Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid-lowering update 2001. Aggressive new goals.

T K Fenske1

  • 1Royal Alexandra Hospital, Edmonton. tfenske@netcom.ca

Canadian Family Physician Medecin De Famille Canadien
|March 3, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human adjuvant disease revisited: a review of eleven post-augmentation mammoplasty patients.

Clinical and experimental rheumatologyยท1994
See all related articles

Lowering cholesterol, particularly low-density lipoprotein (LDL), significantly improves survival and reduces cardiac events in patients with coronary artery disease (CAD). Aggressive risk factor modification is crucial for high-risk individuals.

Area of Science:

  • Cardiology
  • Metabolic Disorders

Background:

  • Cholesterol plays a central role in the development of coronary artery disease (CAD).
  • Identifying patients at high risk for CAD is essential for effective intervention.

Purpose of the Study:

  • To review the role of cholesterol in CAD.
  • To emphasize the importance of identifying high-risk patients.
  • To discuss the treatment of dyslipidemias.

Main Methods:

  • Literature search of MEDLINE (1995-2000) using keywords: cholesterol, risk reduction, statins.
  • Focus on large randomized controlled trials, recent articles, and landmark clinical trials.

Main Results:

  • Lipid-lowering therapies, especially low-density lipoprotein (LDL) reduction, demonstrably improve survival and reduce cardiac events in primary and secondary prevention.

Related Experiment Videos

  • High-risk patient groups now include those with diabetes mellitus, peripheral vascular disease, and established CAD.
  • Comprehensive lipid profiles are necessary for risk assessment and tailored lipid-lowering strategies.

    • Conclusions:

    • Effective and well-tolerated cholesterol-modifying therapies are available.
    • Lipid normalization is a mandatory goal for physicians managing patients with established CAD or those at risk.